Significant Association Between Huntingtin Gene Mutation and Prevalence of Hopelessness, Depression and Anxiety Symptoms
Research papers
Adelė Butėnaitė
Vilnius University, Lithuania
Robertas Strumila
Vilnius University, Lithuania
Aistė Lengvenytė
Vilnius University, Lithuania
Indrė Kotryna Pakutkaitė
Vilnius City Mental Health Center, Lithuania
Aušra Morkūnienė
Vilnius University, Lithuania
Aušra Matulevičienė
Vilnius University, Lithuania
Edgaras Dlugauskas
Vilnius University, Lithuania
Algirdas Utkus
Vilnius University, Lithuania
Published 2021-01-21
https://doi.org/10.15388/Amed.2020.28.1.4
PDF
HTML

Keywords

Huntington’s disease
huntingtin
depression
anxiety
hopelessness

How to Cite

Butėnaitė A., Strumila R., Lengvenytė A., Pakutkaitė I. K., Morkūnienė A., Matulevičienė A., Dlugauskas E. and Utkus A. (2021) “Significant Association Between Huntingtin Gene Mutation and Prevalence of Hopelessness, Depression and Anxiety Symptoms”, Acta medica Lituanica, 28(1), pp. 77-85. doi: 10.15388/Amed.2020.28.1.4.

Abstract

Background: In Huntington’s disease psychiatric symptoms may manifest prior to motor dysfunction. Such symptoms negatively impact people’s quality of life and can worsen the course of the primary disease. The aim of the present study was to assess and compare depression, anxiety and hopelessness rates in individuals with and without an abnormal expansion of CAG repeats in the huntingtin (HTT) gene and healthy controls.
Materials and methods: Study involved 31 individuals referred for genetic testing for Huntington’s disease and a control group of 41. Depressive and anxiety symptoms were assessed using Beck Hopelessness Scale (BHS) and Hospital Anxiety and Depression Scale (HADS). Results between groups were compared using the Mann–Whitney U test. Two-sided Bonferroni corrected p-value was set at ≤0.017.
Results: Individuals with HTT gene mutation (“gene mutation positive”, GMP) (N=20) scored higher on the HADS depression subscale (5.90 ± 4.52 vs 1.36 ± 1.91; p ≤ 0.017) than those without HTT gene mutation (“gene mutation negative”, GMN) (N=11). GMP and control groups scored higher than the GMN group on the BHS (5.65 ± 3.91 vs 2.09 ± 1.64 and 5.27 ± 4.11 vs 2.09 ± 1.64, respectively; p ≤ 0.017). No differences in anxiety levels were found.
Conclusions: Depressive symptoms and hopelessness were more prevalent in individuals with HTT gene mutation than in individuals who were tested but had no said mutation. Such results emphasise the importance of timely diagnosis and treatment of psychiatric comorbidities in individuals affected by Huntington’s disease.

PDF
HTML
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Most read articles by the same author(s)